SCHEMBL1198760

SCHEMBL1198760

OCc1ncc(-c2cccc(C(F)(F)F)c2)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.48
HDAC6 Q9UBN7 2/20 0.47
DYRK1A Q13627 5/20 0.45
DYRK2 Q92630 5/20 0.45
ALDH1A1 P00352 3/20 0.45
GAA P10253 1/20 0.45
ATM Q13315 1/20 0.45
SCN2A Q99250 2/20 0.44
ERCC5 P28715 1/20 0.44
FEN1 P39748 1/20 0.44
CCNA2 P20248 4/20 0.44
CDK2 P24941 4/20 0.44
CDK5 Q00535 4/20 0.44
CDK5R1 Q15078 4/20 0.44
DYRK1B Q9Y463 4/20 0.44
HRH1 P35367 1/20 0.44
HRH4 Q9H3N8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
CCNT1 O60563 3/20 0.42
CDK9 P50750 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2226003 0.81 ERCC5 (0.63) LOXL2ERCC5FEN1CDK2CDK5
SCHEMBL12875717 0.79 HSD17B1 (0.51) LOXL2HDAC6ALDH1A1ERCC5FEN1
SCHEMBL1199228 0.78 ALDH1A1 (0.52) HDAC6ALDH1A1ERCC5FEN1MEN1
SCHEMBL1764981 0.77 ALDH1A1 (0.48) HDAC6DYRK1ADYRK2ALDH1A1GAA
SCHEMBL40156 0.77 ADORA2A (0.49) HDAC6DYRK1ADYRK2ALDH1A1GAA
SCHEMBL12890279 0.77 ALDH1A1 (0.46) LOXL2HDAC6ALDH1A1GAAATM
SCHEMBL18211804 0.75 LOXL2 (0.47) LOXL2ERCC5FEN1
SCHEMBL1198984 0.75 SCN2A (0.47) DYRK1ADYRK2ALDH1A1GAAATM
SCHEMBL13018928 0.75 ALDH1A1 (0.49) HDAC6DYRK1ADYRK2ALDH1A1GAA
SCHEMBL1198441 0.74 MEN1 (0.50) HDAC6ALDH1A1ERCC5FEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A LOXL2 2797/4885HDAC6 2096/4885DYRK1A 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.